Google takes $100M plunge into telehealth

Dave Pearson | | Health Exec | Telehealth
Smartphone mHealth. Updated Twitter policies have helped online pranksters cause mischief in recent days, including one specific user who impersonated Eli Lilly and Company and posted that insulin was now free. Lilly CEO has now commented on the fake tweet read 'round the world—and what it could mean for the company going forward. 

Google Cloud is injecting $100 million into a supplier of telehealth platforms, partly to build out AI systems for helping hospitals remotely handle patient inquiries, intake and triage.

The Silicon Valley behemoth and Boston-based Amwell jointly announced their multipronged plans Aug. 24.

Google Cloud says the $100M investment will be contingent on the closing of Amwell’s upcoming IPO, which also was announced this week.

Among related aims the pair will pursue are translation services via natural language processing, collaboration tools to facilitate staff communications and patient engagement, and data analytics methodologies to monitor patients in homecare settings.

The partnership will allow Amwell (formerly American Well) to refine and scale its telehealth offerings for providers, insurers and patients in current and prospective Amwell markets, according to the joint announcement.

In addition, the partnership will seek to simplify healthcare processes for underserved populations while also helping healthcare workers serve seniors and patients with chronic conditions “in a dramatically new way without compromising on care quality or user trust.”

 

 

Related Telehealth Content:

Patient demand for telemedicine remains strong

Telehealth claims surged in 2020

AMA pushes for equity in telehealth

Walmart acquires telehealth provider MeMD

Telehealth demand starts to soften

More than 200 advocates call on governors to retain telehealth flexibilities

HHS awards $55 million to expand virtual healthcare access

Telehealth visits have declined since the onset of COVID-19

Find more telemedicine stories

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

Association of 300 telehealth groups urges Congress to extend COVID-era rules
Eli Lilly releases cheaper, single-use vials of weight loss drug
Walmart sells virtual care business to Fabric
AMA will aggressively support permanent telemedicine reimbursement
Telehealth execs face 20 years for $100M Adderall prescription fraud
Telemedicine, remote monitoring help reduce healthcare costs

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup